The 8 most recent market catalysts affecting $GLUE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 7, 2026
Corporate Catalyst
Neutral
Impact 55
Wells Fargo Maintains Buy Rating on Monte Rosa Therapeutics, Lowers Price Target
Wells Fargo analyst Derek Archila maintained a 'Buy' rating on Monte Rosa Therapeutics (GLUE), signaling continued confidence in the company's fundamentals. However, the simultaneo…
Oct 5, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a 'Buy' rating on Monte Rosa Therapeutics (GLUE) and maintained a $25 price target. Thi…
Oct 1, 2026
Corporate Catalyst
Bullish
Impact 85
GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?
Monte Rosa Therapeutics (GLUE) experienced a significant pre-market surge of over 20% as investors eagerly await expanded Phase 1 data for its experimental cardiovascular drug, MRT…
Oct 1, 2026
Corporate Catalyst
Neutral
Impact 65
HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. initiating coverage on Monte Rosa Therapeutics with a 'Buy' rating and a $25 price target is a positive development for the company. Analyst coverage, especiall…
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 65
Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations
Monte Rosa Therapeutics (GLUE) has dosed the first patient in its Phase 2 MODeFIRe-1 study for MRT-2359 in mCRPC. This is a positive development as it signifies progress in the cli…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27
JP Morgan analyst Brian Cheng maintained an 'Overweight' rating on Monte Rosa Therapeutics, signaling continued confidence in the company's long-term prospects. However, the price …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate
Monte Rosa Therapeutics (GLUE) reported Q2 earnings per share that missed analyst estimates by a substantial margin, indicating higher-than-anticipated losses. This is a negative s…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27
Wedbush analyst Robert Driscoll maintained an 'Outperform' rating on Monte Rosa Therapeutics (GLUE) but lowered the price target from $37 to $27. This action signals that while the…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.